Brief description of study

A study to assess safety and efficacy of evolocumab (AMG-145) in paediatric subjects aged
10-17 years diagnosed with heterozygous familial hypercholesterolemia.

Detailed Study Description

A study to evaluate the effect of 24 weeks of subcutaneous (SC) evolocumab compared with
placebo,when added to standard of care, on percent change from baseline in lowdensity
lipoprotein cholesterol (LDL-C) in pediatric subjects 10 to 17 years of age with HeFH